141 results on '"Silva, Guilherme Diogo"'
Search Results
2. Identifying high-risk neurological phenotypes in adult-onset classic monogenic autoinflammatory diseases: when should neurologists consider testing?
- Author
-
Silva, Guilherme Diogo, Mahler, João Vitor, da Silva Junior, Sérgio Roberto Pereira, Mendonça, Leonardo Oliveira, de Sá Barreto Lima, Pedro Lucas Grangeiro, Nóbrega, Paulo Ribeiro, Kok, Fernando, and Freua, Fernando
- Published
- 2024
- Full Text
- View/download PDF
3. Controversies in immunotherapy for anti-NMDA receptor encephalitis: a scoping review with a proposal of operational definitions
- Author
-
Bandeira, Geovanni Guimarães, Barreto Lima, Pedro Lucas Grangeiro de Sá, Araújo, David Augusto Batista Sá, Pinheiro, Maria Suelly Nogueira, Albuquerque Mota, Luciano de, Simão, Rafael Machado, de Carvalho, Francisco Matheus Oliveira, Vazquez, Fernando Degani, de Vasconcelos Gama, Vitor Carneiro, de Queiroz, Dánton Campos, da Fonseca Lira, Matheus Zaian Rodrigues, de Oliveira Júnior, Pedro Helder, Guimarães Junior, Fernando Antônio, Caminha, Gabrielle Cavalcante, de Figueiredo Santos, Carolina, Sobreira-Neto, Manoel Alves, Braga-Neto, Pedro, Silva, Guilherme Diogo, and Nóbrega, Paulo Ribeiro
- Published
- 2023
- Full Text
- View/download PDF
4. A Systematic Review on Anti-Yo/PCA-1 Antibody: Beyond Cerebellar Ataxia in Middle-Aged Women with Gynecologic Cancer
- Author
-
Mendes, Natalia Trombini, Ronchi, Nathalia Rossoni, and Silva, Guilherme Diogo
- Published
- 2023
- Full Text
- View/download PDF
5. Systematic review and meta-analysis of galactomannan antigen testing in serum and bronchoalveolar lavage for the diagnosis of chronic pulmonary aspergillosis: defining a cutoff
- Author
-
de Oliveira, Vítor Falcão, Silva, Guilherme Diogo, Taborda, Mariane, Levin, Anna S., and Magri, Marcello Mihailenko Chaves
- Published
- 2023
- Full Text
- View/download PDF
6. A brazilian nationwide multicenter study on deficiency of deaminase-2 (DADA2)
- Author
-
Melo, Adriana, de Carvalho, Luciana Martins, Ferriani, Virginia Paes Leme, Cavalcanti, André, Appenzeller, Simone, Oliveira, Valéria Rossato, Neto, Herberto Chong, Rosário, Nelson Augusto, de Oliveira Poswar, Fabiano, Guimaraes, Matheus Xavier, Kokron, Cristina Maria, Maia, Rayana Elias, Silva, Guilherme Diogo, Keller, Gabriel, Ferreira, Mauricio Domingues, Vasconcelos, Dewton Moraes, Toledo-Barros, Myrthes Anna Maragna, Barros, Samar Freschi, Neto, Nilton Salles Rosa, Krieger, Marta Helena, Kalil, Jorge, and Mendonça, Leonardo Oliveira
- Published
- 2023
- Full Text
- View/download PDF
7. Therapeutic plasma exchange for neuromyelitis optica attacks: Evidence and challenges from a real-world cohort from Brazil
- Author
-
de Almeida, Guilherme Mello Ramos, de Araujo, Roger Santana, Castrillo, Bruno Batitucci, Silva, Guilherme Diogo, Fortini, Ida, Gonçalves, Marcia Rubia Rodrigues, Castro, Luiz Henrique Martins, Tatsui, Nelson Hidekazu, Adoni, Tarso, Sato, Douglas Kazutoshi, Apóstolos-Pereira, Samira Luísa, and Callegaro, Dagoberto
- Published
- 2024
- Full Text
- View/download PDF
8. Vitamin D3 as an add-on treatment for multiple sclerosis: A systematic review and meta-analysis of randomized controlled trials
- Author
-
Mahler, João Vitor, Solti, Marina, Apóstolos-Pereira, Samira Luísa, Adoni, Tarso, Silva, Guilherme Diogo, and Callegaro, Dagoberto
- Published
- 2024
- Full Text
- View/download PDF
9. Risk and characteristics of attacks occurring after vaccination in patients with neuromyelitis optica spectrum disorders: A systematic review and meta-analysis
- Author
-
Silva, Paula Baleeiro Rodrigues and Silva, Guilherme Diogo
- Published
- 2023
- Full Text
- View/download PDF
10. A comparative study of visual outcome in patients with optic neuritis treated with five or seven days of intravenous corticosteroid treatment
- Author
-
Silva, Guilherme Diogo, Terrim, Sara, Falcão, Fernando Cavalcantide Sá e Benevides, Falcão, Maria Alice Pimentel, Chaves, Cleuber Esteves, Apóstolos-Pereira, Samira, Fortini, Ida, Gonçalves, Márcia Rúbia Rodrigues, Comerlatti, Luiz Roberto, Castro, Luiz Henrique Martins, Callegaro, Dagoberto, and Monteiro, Mário Luiz Ribeiro
- Published
- 2023
- Full Text
- View/download PDF
11. Anti-Tr/DNER Antibody–Associated Cerebellar Ataxia: a Systematic Review
- Author
-
Campana, Igor Gusmão and Silva, Guilherme Diogo
- Published
- 2022
- Full Text
- View/download PDF
12. Characteristics and management of Susac syndrome in an emergent country: a multi-center case series from Brazil
- Author
-
Santiago, Igor Bessa, Araújo, Abraão Lazaro Meneses, Nóbrega, Ivna Lacerda Pereira, Silva, Walisson Grangeiro Bringel, Mendes, Lucas Silvestre, Ponte, José Israel Araújo, Dias, Daniel Aguiar, de Castro, José Daniel Vieira, Cunha, Francisco Marcos Bezerra, Sobreira-Neto, Manoel Alves, Braga-Neto, Pedro, Martins, Gabriela Joca, de Aragão, Ricardo Evangelista Marrocos, Silva, Guilherme Diogo, and Nóbrega, Paulo Ribeiro
- Published
- 2022
- Full Text
- View/download PDF
13. Cost, efficacy, and safety comparison between early intensive and escalating strategies for multiple sclerosis: A systematic review and meta-analysis
- Author
-
Pipek, Leonardo Zumerkorn, Mahler, João Vitor, Nascimento, Rafaela Farias Vidigal, Apóstolos-Pereira, Samira Luísa, Silva, Guilherme Diogo, and Callegaro, Dagoberto
- Published
- 2023
- Full Text
- View/download PDF
14. Estimated prevalence of AQP4 positive neuromyelitis optica spectrum disorder and MOG antibody associated disease in São Paulo, Brazil
- Author
-
Silva, Guilherme Diogo, Apóstolos-Pereira, Samira Luisa, and Callegaro, Dagoberto
- Published
- 2023
- Full Text
- View/download PDF
15. Real-world application of the 2022 diagnostic criteria for first-ever episode of optic neuritis
- Author
-
Terrim, Sara, Silva, Guilherme Diogo, de Sá e Benevides Falcao, Fernando Cavalcanti, dos Reis Pereira, Clarissa, de Souza Andrade Benassi, Thais, Fortini, Ida, Gonçalves, Marcia Rubia Rodrigues, Castro, Luiz Henrique Martins, Comerlatti, Luiz Roberto, de Medeiros Rimkus, Carolina, Adoni, Tarso, Pereira, Samira Luisa Apostolos, Monteiro, Mário Luiz, and Callegaro, Dagoberto
- Published
- 2023
- Full Text
- View/download PDF
16. Association between neuroimaging and clinical outcomes in individuals with central nervous system cryptococcosis.
- Author
-
Teixeira, Juliana Cavadas, de Oliveira, Vítor Falcão, Gomes, Hélio Rodrigues, Ribeiro, Suzana Mesquita, de Araujo, Evangelina da Motta Pacheco Alves, da Cruz, Isabela Carvalho Leme Vieira, Taborda, Mariane, Magri, Adriana Satie Gonçalves Kono, Vidal, José Ernesto, Nastri, Ana Catharina de Seixas Santos, Silva, Guilherme Diogo, and Magri, Marcello Mihailenko Chaves
- Subjects
CENTRAL nervous system ,CRYPTOCOCCOSIS ,MAGNETIC resonance imaging ,TREATMENT effectiveness ,BRAIN imaging - Abstract
Background: The radiological manifestations of central nervous system (CNS) cryptococcosis are diverse and often subtle. There is heterogeneity on how different neuroimaging patterns impact prognosis. This study aims to assess the association between the neuroimaging and clinical outcomes of CNS cryptococcosis. Methods: All patients with CNS cryptococcosis between July 2017 and April 2023 who underwent brain magnetic resonance imaging (MRI) were included. The primary outcome was mortality during hospitalisation. Secondary outcomes were readmission, ventricular shunting, duration of hospitalisation and time to the first negative cerebrospinal fluid culture. We compared the outcomes for each of the five main radiological findings on the brain MRI scan. Results: We included 46 proven CNS cryptococcosis cases. The two main comorbidity groups were HIV infection (20, 43%) and solid organ transplantation (10, 22%), respectively. Thirty‐nine patients exhibited at least one radiological abnormality (85%), with the most common being meningeal enhancement (34, 74%). The mortality rates occurred at 11% (5/46) during hospitalisation. We found no significant disparities in mortality related to distinct radiological patterns. The presence of pseudocysts was significantly associated with the need for readmission (p =.027). The ventricular shunting was significantly associated with the presence of pseudocysts (p =.005) and hydrocephalus (p =.044). Conclusion: In this study, there is no association between brain MRI findings and mortality. Larger studies are needed to evaluate this important issue. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
17. Considering a new clinical presentation of the anti-Tr/DNER antibody-associated cerebellar ataxia
- Author
-
Campana, Igor Gusmão and Silva, Guilherme Diogo
- Published
- 2023
- Full Text
- View/download PDF
18. Myelopathy in sickle cell disease: a case-oriented review
- Author
-
Brum, Igor Vilela, Silva, Guilherme Diogo, Sodre, Diego Sant’Ana, Nogueira, Felipe Melo, Pereira, Samira Luisa dos Apostolos, and Castro, Luiz Henrique Martins
- Published
- 2021
- Full Text
- View/download PDF
19. Clinical characteristics, diagnosis, and treatment of central nervous system sporotrichosis: Systematic review and meta‐analysis.
- Author
-
de Oliveira, Vítor Falcão, Petrucci, Júlia Figueiredo, Taborda, Mariane, Brener, Pedro Zanetta, Kremer, Pedro Guilherme De Barros Brito, Randi, Bruno Azevedo, Magri, Adriana Satie Gonçalves Kono, Magri, Marcello Mihailenko Chaves, Levin, Anna S., and Silva, Guilherme Diogo
- Subjects
CENTRAL nervous system ,SPOROTRICHOSIS ,HIV infections ,IMMUNOCOMPROMISED patients ,INFECTION - Abstract
Background: The clinical features of central nervous system (CNS) sporotrichosis are derived from case reports and a limited series of cases. Our objective was to carry out a systematic review and meta‐analysis of CNS sporotrichosis. Methods: We searched PubMed/MEDLINE, Embase, Scopus, and LILACS on 9 September 2023. Our inclusion criteria were documentation of Sporothrix and demonstrated CNS involvement. A metaproportion or metamean analysis was performed to estimate a summary proportion with 95% confidence intervals. Results: We included 52 cases of CNS sporotrichosis published from 1966 to 2023. Forty‐six patients were male (88%, 95% CI: 77–95), and the mean age was 39 years (95% CI: 36–43). Close contact with cats was reported in 55% of cases (95% CI: 37–72). Thirty‐two (61.5%) patients were from Brazil, 18 patients from the United State of America (34.6%). Only two Sporothrix species were reported: S. schenckii (26/41, 63%), and S. brasiliensis (15/41, 37%). The most common neurological symptom was headache. Meningitis was chronic in approximately 80% of cases. A significant majority of the patients were immunocompromised. HIV infection was the primary cause of immunosuppression (85%, 95% CI: 61–95). Overall mortality was 56% (22/39). The comparison of Kaplan–Meier survival curve showed a higher mortality with a statistically significant difference in immunosuppressed patients (p =.019). Conclusion: CNS sporotrichosis represents a notable cause of chronic meningitis, especially in individuals living in the Americas with HIV infection and concurrent skin lesions. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
20. Misdiagnosis in multiple sclerosis in a Brazilian reference center: Clinical, radiological, laboratory profile and failures in the diagnostic process—Cohort study.
- Author
-
Tieppo, Eduardo Macedo de Souza, Silva, Guilherme Diogo, Silva, Tomás Fraga Ferreira da, Araujo, Roger Santana de, Oliveira, Mateus Boaventura de, Spricigo, Mariana Gondim Peixoto, Pimentel, Gabriela Almeida, Campana, Igor Gusmão, Castrillo, Bruno Batitucci, Mendes, Natalia Trombini, Teixeira, Larissa Silva, Nunes, Douglas Mendes, Rimkus, Carolina de Medeiros, Adoni, Tarso, Apóstolos Pereira, Samira Luisa, and Callegaro, Dagoberto
- Subjects
- *
MULTIPLE sclerosis , *DIAGNOSTIC errors , *DEMYELINATION , *NEUROMYELITIS optica - Abstract
Background: Multiple sclerosis misdiagnosis remains a problem despite the well-validated McDonald 2017. For proper evaluation of errors in the diagnostic process that lead to misdiagnosis, it is adequate to incorporate patients who are already under regular follow-up at reference centers of demyelinating diseases. Objectives: To evaluate multiple sclerosis misdiagnosis in patients who are on follow-up at a reference center of demyelinating diseases in Brazil. Methods: We designed an observational study including patients in regular follow-up, who were diagnosed with multiple sclerosis at our specialized outpatient clinic in the Hospital of Clinics in the University of Sao Paulo, from 1996 to 2021, and were reassessed for misdiagnosis in 2022. We evaluated demographic information, clinical profile, and complementary exams and classified participants as "established multiple sclerosis," "non-multiple sclerosis, diagnosed," and "non-multiple sclerosis, undiagnosed." Failures in the diagnostic process were assessed by the modified Diagnostic Error Evaluation and Research tool. Results: A total of 201 patients were included. After analysis, 191/201 (95.02%) participants were confirmed as "established multiple sclerosis," 5/201 (2.49%) were defined as "non-multiple sclerosis, diagnosed," and 5/201 (2.49%) were defined as "non-multiple sclerosis, undiagnosed." Conclusions: Multiple sclerosis misdiagnosis persists in reference centers, emphasizing the need for careful interpretation of clinical findings to prevent errors. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
21. Supratentorial Lymphocytic Inflammation with Parenchymal Perivascular Enhancement Responsive to Steroids (SLIPPERS)—Does it Really Exist?
- Author
-
Freua, Fernando, Mahler, João Vitor, Lima, Pedro Lucas Grangeiro de Sá Barreto, Neville, Iuri Santana, Portella, Leonardo Barreira, Marussi, Victor Hugo Rocha, Lancellotti, Carmen Lucia Penteado, Nobrega, Paulo Ribeiro, and Silva, Guilherme Diogo
- Subjects
MAGNETIC resonance imaging ,INFLAMMATION ,SARCOIDOSIS ,STEROIDS ,WHITE matter (Nerve tissue) - Abstract
Supratentorial Lymphocytic Inflammation with Parenchymal Perivascular Enhancement Responsive to Steroids (SLIPPERS) is a rare variant of the CLIPPERS spectrum with less than ten reports published so far. There is ongoing discussion regarding whether SLIPPERS is a disease entity on its own or just an acronym encompassing many underlying diagnoses, such as sarcoidosis, vasculitis and anti-glial fibrillary acidic protein (GFAP)-associated disease. A 40-year-old woman presented with episodes of language and attention impairment. Magnetic resonance imaging (MRI) revealed T2/FLAIR hyperintense lesions in the subcortical white matter associated with a micronodular, curvilinear perivascular contrast-enhancement. Alternative diagnoses were excluded. There was a remarkable response to steroids. A relapse occurred after six years, and the biopsy showed perivascular T-cell lymphocytic infiltrate, without granulomas, vasculitis, or neoplasia. There was complete resolution of the relapse after steroids. This case represents the longest reported follow-up of a patient diagnosed with SLIPPERS, and brain biopsy after 6 years did not suggest alternative diagnoses. This report contributes to the discussion regarding the possibility that exclusive supratentorial CLIPPERS-like pathology might be an isolated disease entity, but more biopsy-proven cases with a longer follow-up are needed to support this hypothesis. Recently, GFAP astrocytopathy has been characterized and might correspond to a significant number of cases previously diagnosed as CLIPPERS or SLIPPERS. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
22. Clinical, radiological and laboratory characteristics of central nervous system histoplasmosis: A systematic review of a severe disease.
- Author
-
de Oliveira, Vítor Falcão, Kruschewsky, Wdson Luis Lima, Sekiguchi, William Kazunori, Costa, Silvia F., Levin, Anna S., Magri, Marcello Mihailenko Chaves, and Silva, Guilherme Diogo
- Subjects
CENTRAL nervous system ,HISTOPLASMOSIS ,ITRACONAZOLE ,AMPHOTERICIN B ,YOUNG adults ,HIV infections - Abstract
Background: The knowledge of central nervous system (CNS) histoplasmosis is limited to case reports and series. Objectives: Our objective was to synthesise clinical, radiological and laboratory characteristics of CNS histoplasmosis to improve our understanding of this rare disease. Methods: We performed a systematic review using Pubmed/MEDLINE, Embase and LILACS databases accessed on March 2023 without publication date restrictions. Inclusion criteria comprised: (1) histopathological, microbiological, antigen or serological evidence of histoplasmosis; (2) CNS involvement based on cerebrospinal fluid pleocytosis or neuroimaging abnormalities. We classified the certainty of the diagnosis in proven (CNS microbiological and histopathological confirmation), probable (CNS serological and antigen confirmation) or possible (non‐CNS evidence of histoplasmosis). Metaproportion was used to provide a summary measure with 95% confidence intervals for the clinical, radiological and laboratory characteristics. Chi‐squared test was used to compare mortality between pairs of antifungal drugs. Results: We included 108 studies with 298 patients. The median age was 31 years, predominantly male, and only 23% were immunocompromised (134/276, 95%CI: 3–71), mainly due to HIV infection. The most common CNS symptom was headache (130/236, 55%, 95%CI: 49–61), with a duration predominantly of weeks or months. Radiological presentation included histoplasmoma (79/185, 34%, 95%CI: 14–61), meningitis (29/185, 14%, 95%CI: 7–25), hydrocephalus (41/185, 37%, 95%CI: 7–83) and vasculitis (18/185, 6%, 95%CI: 1–22). There were 124 proven cases, 112 probable cases and 40 possible cases. The majority of patients presented positive results in CNS pathology (90%), serology (CSF: 72%; serum: 70%) or CSF antigen (74%). Mortality was high (28%, 56/198), but lower in patients who used liposomal amphotericin B and itraconazole. Relapse occurred in 13% (23/179), particularly in HIV patients, but less frequently in patients who used itraconazole. Conclusion: Central nervous system histoplasmosis usually presents subacute‐to‐chronic symptoms in young adults. Neuroimaging patterns included not only focal lesions but also hydrocephalus, meningitis and vasculitis. Positive results were commonly found in CSF antigen and serology. Mortality was high, and treatment with liposomal amphotericin B followed by itraconazole may decrease mortality. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
23. Prophylactic antiseizure drugs for spontaneous intracerebral hemorrhage: An updated systematic review and meta-analysis.
- Author
-
Mota Telles, João Paulo, Rocha, Rebeka Bustamante, Cenci, Giulia Isadora, Nager, Gabriela Borges, Silva, Guilherme Diogo, and Figueiredo, Eberval Gadelha
- Subjects
CEREBRAL hemorrhage ,DRUGS ,ODDS ratio ,FUNCTIONAL status ,PATIENT monitoring - Abstract
Background: There is concern that recommendations on prophylactic antiseizure drugs (PASDs) for patients with spontaneous intracerebral hemorrhage (sICH) are biased by studies using older drugs and no electrographic monitoring. Aims: We performed a systematic review and meta-analysis to determine whether PASDs in patients with sICH reduced seizure occurrence and improved functional outcomes. We included analyses of newer trials, newer antiseizure drugs, and effectiveness in patients with consistent electrographic monitoring. Methods: Medline, Embase, and Cochrane were searched from inception until 12 August 2022, to identify studies with patients with sICH treated with PASDs, regardless of study design. The studied outcomes were functional status and occurrence of seizures. Results: Fourteen studies were included, including 6742 patients. Risk of bias was low overall. There was no effect of PASD on seizure occurrence overall (odds ratio (OR) 0.73, 95% confidence interval (CI) 0.47–1.15), but they were associated with reduced occurrence in studies with electrographic monitoring (OR 0.36, 95% CI 0.18–0.70). There was no effect of PASDs on functional outcomes (OR 1.15; 95% CI 0.91–1.47) or mortality (OR 0.85, 95% CI 0.65–1.11). Conclusion: Prophylactic antiseizure medications after sICH reduce seizures in studies with electroencephalogram monitoring in high-risk patients. However, this benefit did not reflect in the improvement of functional outcomes, even in studies with newer, less toxic, antiseizure drugs. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
24. Paracentral Acute Middle Maculopathy Associated with Severe Anti-Mog (Myelin Oligodendrocyte Glycoprotein)-Positive Optic Neuritis.
- Author
-
Fernandes, Rodrigo Dahia, de Souza Andrade, Thais, Preti, Rony C., Zacharias, Leandro C., Silva, Guilherme Diogo, Lucato, Leandro Tavares, Apóstolos-Pereira, Samira L., Callegaro, Dagoberto, and Monteiro, Mário Luiz R.
- Subjects
MYELIN oligodendrocyte glycoprotein ,OPTIC neuritis ,NEUROMYELITIS optica ,MACULAR degeneration ,OPTICAL coherence tomography ,MULTIPLE sclerosis - Abstract
Retinal complications in patients with inflammatory optic neuritis (ON) are generally related to post-infectious neuroretinitis and are considered uncommon in autoimmune/demyelinating ON, whether isolated or caused by multiple sclerosis (MS) or neuromyelitis optica spectrum disorder (NMOSD). More recently, however, cases with retinal complications have been reported in subjects positive for myelin oligodendrocyte glycoprotein (MOG) antibodies. We report a 53-year-old woman presenting with severe bilateral ON associated with a focal area of paracentral acute middle maculopathy (PAMM) in one eye. Visual loss recovered remarkably after high-dose intravenous corticosteroid treatment and plasmapheresis, but the PAMM lesion remained visible on both optical coherence tomography and angiography as an ischaemic lesion affecting the middle layers of the retina. The report emphasises the possible occurrence of retinal vascular complications in MOG–related optic neuritis, an important addition to the diagnosis of, and possible differentiation from, MS–related or NMOSD–related ON. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
25. Letter to the Editor: Is it time to expand the clinical spectrum of transient global amnesia?
- Author
-
Ramos, Gabriel Bortoli, Lopes, Cesar Castelo Branco, Comerlatti, Luiz Roberto, Studart-Neto, Adalberto, and Silva, Guilherme Diogo
- Published
- 2022
- Full Text
- View/download PDF
26. Letter to the editor: Should we stop using post-contrast sequences in the follow-up MRI of patients with multiple sclerosis?
- Author
-
Mahler, João Vitor and Silva, Guilherme Diogo
- Published
- 2022
- Full Text
- View/download PDF
27. Challenges and insights in immunization in patients with demyelinating diseases: a bench-to-bedside and evidence-based review
- Author
-
Silva, Guilherme Diogo, Oliveira, Vítor Falcão de, and Mendonça, Leonardo Oliveira
- Subjects
Vaccines ,Vacinas ,Multiple Sclerosis ,Imunização ,Neuromielite Óptica ,Esclerose Múltipla ,Neuromyelitis Optica ,Immunization ,Doenças Desmielinizantes ,Demyelinating Diseases - Abstract
Background: Infections are among the main causes of death in patients with demyelinating diseases of the central nervous system (CNSDD). Vaccines are effective methods in reducing hospitalization and death from infectious diseases, but they are challenging in patients with CNSDD because of autoimmunity and immunosuppression. Objectives: To summarize the pathophysiological rationale and main evidence for vaccine recommendations in patients with CNSDD. Methods: Specialists with different backgrounds on the subject: a neurologist specialized in demyelinating diseases, an infectious diseases specialist and an immunologist, presented a critical narrative review of vaccination literature in patients with CNSDD, highlighting which vaccines should or should not be administered and the best time for it. Results: Patients with DDSNC are at increased risk of vaccine-preventable viral and bacterial infections. Vaccines can prevent herpes zoster, hepatitis B reactivation, HPV-associated warts and tumors, viral and bacterial pneumonia, and meningitis. Live attenuated virus vaccines should not be used when the patient is on immunosuppression. Vaccines should be avoided during relapses. The greatest vaccine efficacy is given before treatment or at the end of medication. Conclusion: Patients with DDSNC need differentiated immunization in relation to additional vaccines, contraindicated vaccines and timing of vaccination. RESUMO Antecedentes: Infecções estão entre as principais causas de morte de pacientes com doenças desmielinizantes do sistema nervoso central (DDSNC). Vacinas são métodos eficazes para reduzir internação e morte por doenças infecciosas, porém são desafiadoras em pacientes com DDSNC tanto pela autoimunidade quanto pela imunossupressão. Objetivos: Resumir o racional fisiopatológico e as principais evidências para as recomendações de vacinas em pacientes com DDSNC. Métodos: Especialistas com diferentes formações no tema: um neurologista especialista em doenças desmielinizantes, um infectologista e um imunologista, apresentam uma revisão crítica narrativa da Literatura de vacinação em pacientes com DDSNC, com destaque a quais vacinas devem ou não ser administradas e o melhor momento para isso. Resultados: Pacientes com DDSNC têm risco aumentado para infecções imunopreveníveis virais e bacterianas. Vacinas podem prevenir herpes zooster, reativação de hepatite B, verrugas e tumores associados ao HPV, pneumonias virais e bacterianas, além de meningites. Vacinas de vírus vivos atenuados não devem ser usadas quando o paciente está em uso de imunossupressão. Vacinas devem ser evitadas durante surtos. A maior eficácia vacinal é dada antes do tratamento ou ao final de doses de medicações. Conclusão: Os pacientes com DDSNC necessitam de imunização diferenciada em relação a vacinas adicionais, vacinas contraindicadas e melhor momento de vacinação.
- Published
- 2022
28. Systematic review of neuroparacoccidioidomycosis: The contribution of neuroimaging.
- Author
-
de Oliveira, Vítor Falcão, Magri, Marcello Mihailenko Chaves, Levin, Anna S., and Silva, Guilherme Diogo
- Subjects
MAGNETIC resonance imaging ,BRAIN imaging ,BRAIN damage ,PARACOCCIDIOIDOMYCOSIS ,EARLY diagnosis - Abstract
Background: Advanced neuroimaging demonstrated that neurological involvement occurs in up to 30% of paracoccidioidomycosis (PCM) cases. Current knowledge of neuroparacoccidioidomycosis (NPCM) is based on a 2009 systematic review. However, in the last decade, several new cases have been published, with modern neuroimaging techniques. Objectives: We believe a new systematic review is needed to summarise these advances. Methods: We searched PubMed/MEDLINE, Embase and LILACS for studies from January 2010 to May 2022. Case series and case reports of NPCM were included. We performed a metaproportion to estimate a summary proportion with 95% confidence intervals (CI). Results: Thirty‐four studies including 104 patients were evaluated. We combined our data with the results from the previous review that included 257 cases, totalling 361 patients. We found no new important demographic, clinical or laboratory characteristics. On magnetic resonance imaging (MRI), we found that 72% (95%CI: 38–91) had hyperintensity on T1‐weighted image; 84% (95%CI: 71%–92%) had hypointensity on T2‐weighted image; 80% (95%CI: 66–89) had contrast enhancement with the classical ring‐enhancing pattern. All 8 patients undergoing spectroscopy presented lipid peaks. We found a 16% mortality, lower than in the previous review (44%). Conclusion: NPCM presents a characteristic pattern on MRI that may help to differentiate it from other causes of single or multiple brain lesions. Albeit there is a frequent pattern, it is not specific, as other granulomatous diseases may show similar findings. Advances in neuroimaging with early diagnosis and appropriate management of the disease may have contributed to reducing its mortality. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
29. ROMBENCEFALITE POR ESQUISTOSSOMOSE: RELATO DE CASO
- Author
-
Guimarães, Lara Silva Pereira, Santos, Diego Augusto Medeiros, Mari, Julia Ferreira, Baer, Alice de Paula, Pinto, Agnes Araújo Sardinha, Ribeiro, Mateus Barradas, de Oliveira, Vitor Falcão, Silva, Beatriz Carneiro Gondim, Silva, Guilherme Diogo, Medeiros, Maria Felipe, Teixeira, Juliana Cavadas, and Litvoc, Marcelo Nóbrega
- Published
- 2022
- Full Text
- View/download PDF
30. Recommendations by the Scientific Department of Neuroimmunology of the Brazilian Academy of Neurology (DCNI/ABN) and the Brazilian Committee for Treatment and Research in Multiple Sclerosis and Neuroimmunological Diseases (BCTRIMS) on vaccination in general and specifically against SARS-CoV-2 for patients with demyelinating diseases of the central nervous system
- Author
-
Becker, Jefferson, Ferreira, Lis Campos, Damasceno, Alfredo, Bichuetti, Denis Bernardi, Christo, Paulo Pereira, Callegaro, Dagoberto, Peixoto, Marco Aurélio Lana, Sousa, Nise Alessandra De Carvalho, Almeida, Sérgio Monteiro De, Adoni, Tarso, Santiago-Amaral, Juliana, Junqueira, Thiago, Pereira, Samira Luisa Apóstolos, Gomes, Ana Beatriz Ayroza Galvão Ribeiro, Pitombeira, Milena, Paolilo, Renata Barbosa, Grzesiuk, Anderson Kuntz, Piccolo, Ana Claudia, D´Almeida, José Arthur Costa, Gomes Neto, Antonio Pereira, Oliveira, Augusto Cesar Penalva De, Oliveira, Bianca Santos De, Tauil, Carlos Bernardo, Vasconcelos, Claudia Ferreira, Kaimen-Maciel, Damacio, Varela, Daniel, Diniz, Denise Sisterolli, Oliveira, Enedina Maria Lobato De, Malfetano, Fabiola Rachid, Borges, Fernando Elias, Figueira, Fernando Faria Andrade, Gondim, Francisco De Assis Aquino, Passos, Giordani Rodrigues Dos, Silva, Guilherme Diogo, Olival, Guilherme Sciascia Do, Santos, Gutemberg Augusto Cruz Dos, Ruocco, Heloisa Helena, Sato, Henry Koiti, Soares Neto, Herval Ribeiro, Cortoni Calia, Leandro, Gonçalves, Marcus Vinícius Magno, Vecino, Maria Cecilia Aragón De, Pimentel, Maria Lucia Vellutini, Ribeiro, Marlise De Castro, Boaventura, Mateus, Parolin, Mônica Koncke Fiuza, Melo, Renata Brant De Souza, Lázaro, Robson, Thomaz, Rodrigo Barbosa, Kleinpaul, Rodrigo, Dias, Ronaldo Maciel, Gomes, Sidney, Lucatto, Simone Abrante, Alves-Leon, Soniza Vieira, Fukuda, Thiago, Ribeiro, Taysa Alexandrino Gonsalves Jubé, Winckler, Thereza Cristina D’ávila, Fragoso, Yara Dadalti, Nascimento, Osvaldo José Moreira Do, Ferreira, Maria Lucia Brito, Mendes, Maria Fernanda, Brum, Doralina Guimarães, Glehn, Felipe Von, Pontifícia Universidade Católica Do Rio Grande Do Sul, Universidade Federal de Sergipe (UFS), Universidade Tiradentes, Universidade Estadual de Campinas (UNICAMP), Universidade Federal de São Paulo (UNIFESP), Universidade Federal de Minas Gerais (UFMG), Universidade de São Paulo (USP), Universidade Federal Do Amazonas, Universidade Federal do Paraná (UFPR), Hospital Sírio Libanês, Escola Bahiana de Medicina e Saúde Pública, Hospital Geral de Fortaleza, Clínica Nossa Senhora das Graças, Hospital Santa Marcelina, Santa Casa, Instituto de Infectologia Emílio Ribas, Fundação Centro Integrado de Apoio Ao Portador de Deficiência, Secretaria de Estado da Saúde, Universidade Federal do Rio de Janeiro (UFRJ), Hospital de Clínicas de Passo Fundo, Universidade Federal de Goiás (UFG), Universidade Estácio de Sá, Hospital São Francisco Na Providência de Deus, Universidade Federal Do Ceará, Associação Brasileira de Esclerose Múltipla, Universidade Federal Fluminense (UFF), Pontifícia Universidade Católica, Instituto de Neurologia de Curitiba, IAMSPE, Private Service, Universidade da Região de Joinville, Hospital Moinhos de Vento, Universidade Federal Ciências da Saúde de Porto Alegre, Faculdade de Medicina de Jundiaí, Hospital Israelita Albert Einstein, Hospital de Base Do Distrito Federal, Hospital Beneficiência Portuguesa, Hospital Regional de Vilhena, Universidade Federal Do Estado Do Rio de Janeiro, Hospital Universitário Prof. Edgar Santos, Universidade Metropolitana de Santos, Hospital da Restauração, Universidade Estadual Paulista (UNESP), and Universidade de Brasília (UnB)
- Subjects
Vacinação ,Multiple Sclerosis ,Doenças Autoimunes Desmielinizantes do Sistema Nervoso Central ,Neuromielite Óptica ,SARS-CoV-2 ,Esclerose Múltipla ,Vaccination ,Neuromyelitis Optica ,COVID-19 ,Demyelinating Autoimmune Diseases, CNS - Abstract
Made available in DSpace on 2022-04-29T08:46:09Z (GMT). No. of bitstreams: 0 Previous issue date: 2021-11-01 The Scientific Department of Neuroimmunology of the Brazilian Academy of Neurology (DCNI/ABN) and Brazilian Committee for Treatment and Research in Multiple Sclerosis and Neuroimmunological Diseases (BCTRIMS) provide recommendations in this document for vaccination of the population with demyelinating diseases of the central nervous system (CNS) against infections in general and against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes COVID-19. We emphasize the seriousness of the current situation in view of the spread of COVID-19 in our country. Therefore, reference guides on vaccination for clinicians, patients, and public health authorities are particularly important to prevent some infectious diseases. The DCNI/ABN and BCTRIMS recommend that patients with CNS demyelinating diseases (e.g., MS and NMOSD) be continually monitored for updates to their vaccination schedule, especially at the beginning or before a change in treatment with a disease modifying drug (DMD). It is also important to note that vaccines are safe, and physicians should encourage their use in all patients. Clearly, special care should be taken when live attenuated viruses are involved. Finally, it is important for physicians to verify which DMD the patient is receiving and when the last dose was taken, as each drug may affect the induction of immune response differently. Pontifícia Universidade Católica Do Rio Grande Do Sul, RS Universidade Federal de Sergipe, SE Universidade Tiradentes, SE Universidade de Campinas Faculdade de Ciências Médicas, SP Universidade Federal de São Paulo Escola Paulista de Medicina, SP Universidade Federal de Minas Gerais, MG Universidade de São Paulo Faculdade de Medicina Hospital das Clínicas, SP Universidade Federal Do Amazonas, AM Universidade Federal Do Paraná, PR Hospital Sírio Libanês, SP Escola Bahiana de Medicina e Saúde Pública, BA Hospital Geral de Fortaleza, CE Clínica Nossa Senhora das Graças, MS Hospital Santa Marcelina, SP Santa Casa, MG Instituto de Infectologia Emílio Ribas, SP Fundação Centro Integrado de Apoio Ao Portador de Deficiência, PB Secretaria de Estado da Saúde, DF Universidade Federal Do Rio de Janeiro, RJ Santa Casa, PR Hospital de Clínicas de Passo Fundo, RS Universidade Federal de Goiás, GO Universidade Estácio de Sá, RJ Hospital São Francisco Na Providência de Deus, RJ Universidade Federal Do Ceará, CE Associação Brasileira de Esclerose Múltipla, SP Santa Casa, SP Universidade Federal Fluminense, RJ Pontifícia Universidade Católica, SP Instituto de Neurologia de Curitiba, PR IAMSPE, SP Private Service, SP Universidade da Região de Joinville, SC Hospital Moinhos de Vento, RS Santa Casa, RJ Universidade Federal Ciências da Saúde de Porto Alegre, RS Faculdade de Medicina de Jundiaí, SP Hospital Israelita Albert Einstein, SP Hospital de Base Do Distrito Federal, DF Hospital Beneficiência Portuguesa, SP Hospital Regional de Vilhena, RO Universidade Federal Do Estado Do Rio de Janeiro, RJ Hospital Universitário Prof. Edgar Santos, BA Universidade Metropolitana de Santos, SP Hospital da Restauração, PE Universidade Estadual Paulista Faculdade de Medicina de Botucatu, SP Universidade de Brasília Faculdade de Medicina, DF Universidade Estadual Paulista Faculdade de Medicina de Botucatu, SP
- Published
- 2021
31. Is there a role for off‐label high‐efficacy disease‐modifying drugs in progressive multiple sclerosis? A network meta‐analysis.
- Author
-
Silva, Guilherme Diogo, Castrillo, Bruno Batitucci, Apóstolos‐Pereira, Samira Luísa, and Callegaro, Dagoberto
- Subjects
- *
MULTIPLE sclerosis , *CLINICAL trials , *DRUGS , *NATALIZUMAB , *PLACEBOS - Abstract
Ocrelizumab and siponimod are the two on‐label drugs used for progressive forms of multiple sclerosis (PMS). However, many patients with PMS do not have access to these high‐efficacy disease‐modifying drugs (DMDs). Off‐label prescription of other high‐efficacy DMDs (fingolimod, rituximab and natalizumab) may be a strategy to improve access to immunotherapy for these patients. We aim to compare on‐label and off‐label high‐efficacy drugs for their effect on disability progression in PMS. In December 2021, we searched MEDLINE (PubMed), Embase, Cochrane Central and Scopus databases for randomized clinical trials involving patients with PMS. High‐efficacy drugs were considered as intervention and placebos as comparison. The outcome contemplated was risk of Expanded Disability Severity Scale (EDSS) progression at 2 years. A network meta‐analysis was performed to compare the relative risk of EDSS progression at 2 years compared with placebo in on‐label and off‐label drugs. We included five studies with 4526 patients. The median EDSS progression at 2 years in patients that received any immunotherapy was 30%, compared with 35% in placebo groups. Overall, the risk of bias of individual studies was low. Network analysis revealed overlapping confidence intervals in off‐label drugs (CI95% 0.51–2.16) versus ocrelizumab (reference) and off‐label drugs (CI 95% 0.53–1.96) versus siponimod (reference), suggesting similar efficacy. The same result was found even after excluding studies with the risk of publication bias. Off‐label high efficacy immunotherapy in PMS has biological plausibility and presented similar effectiveness to on‐label DMDs in this network meta‐analysis. The use of fingolimod, rituximab or natalizumab may be a strategy that reduces costs and improves access to immunotherapy for patients with PMS. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
32. Controversies and Clinical Applications of Non-Invasive Transspinal Magnetic Stimulation: A Critical Review and Exploratory Trial in Hereditary Spastic Paraplegia.
- Author
-
Carra, Rafael Bernhart, Silva, Guilherme Diogo, Paraguay, Isabela Bruzzi Bezerra, Diniz de Lima, Fabricio, Menezes, Janaina Reis, Pineda, Aruane Mello, Nunes, Glaucia Aline, Simões, Juliana da Silva, França Jr., Marcondes Cavalcante, and Cury, Rubens Gisbert
- Subjects
- *
SPASTICITY , *FAMILIAL spastic paraplegia , *TRANSCRANIAL magnetic stimulation , *SPINAL cord , *NEUROLOGICAL disorders , *MENTAL illness , *PARKINSON'S disease - Abstract
Magnetic stimulation is a safe, non-invasive diagnostic tool and promising treatment strategy for neurological and psychiatric disorders. Although most studies address transcranial magnetic stimulation, transspinal magnetic stimulation (TsMS) has received recent attention since trials involving invasive spinal cord stimulation showed encouraging results for pain, spasticity, and Parkinson's disease. While the effects of TsMS on spinal roots is well understood, its mechanism of action on the spinal cord is still controversial. Despite unclear mechanisms of action, clinical benefits of TsMS have been reported, including improvements in scales of spasticity, hyperreflexia, and bladder and bowel symptoms, and even supraspinal gait disorders such as freezing and camptocormia. In the present study, a critical review on the application of TsMS in neurology was conducted, along with an exploratory trial involving TsMS in three patients with hereditary spastic paraplegia. The goal was to understand the mechanism of action of TsMS through H-reflex measurement at the unstimulated lumbosacral level. Although limited by studies with a small sample size and a low to moderate effect size, TsMS is safe and tolerable and presents consistent clinical and neurophysiological benefits that support its use in clinical practice. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
33. A critical review and update on autoimmune encephalitis: understanding the alphabet soup.
- Author
-
SIMABUKURO, Mateus Mistieri, da SILVA, Guilherme Diogo, CASTRO, Luiz Henrique Martins, and LUCATO, Leandro Tavares
- Abstract
Copyright of Arquivos de Neuro-Psiquiatria is the property of Thieme Medical Publishing Inc. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2022
- Full Text
- View/download PDF
34. Outcomes of acute basilar artery occlusion—real‐world experience in a middle‐income country.
- Author
-
Del Guerra, Felipe Borelli, Silva, Guilherme Diogo, Perissinoti, Iago Navas, Morais, Livia, Marsolla, Felipe Lorenzo Dornelas, Comerlatti, Luiz Roberto, Puglia Junior, Paulo, and Conforto, Adriana Bastos
- Subjects
- *
BASILAR artery , *ARTERIAL occlusions , *MIDDLE-income countries , *NIH Stroke Scale , *INTRACRANIAL hemorrhage - Abstract
Objectives: Our goal was to describe outcomes in a single‐center, real‐world series of patients with acute basilar artery occlusion in a middle‐income country. In addition, we assessed potential outcome predictors. Material and Methods: Data from 28 patients were retrospectively reviewed. The primary outcome was death until last follow‐up. Other outcomes were rates of favorable outcome until last follow‐up and rates of intracranial hemorrhage. Outcomes were compared in subgroups according to several variables, including reperfusion (REP group) or no reperfusion (NOREP group) interventions, with chi‐squared, Fisher's exact test, or Mann–Whitney tests. Results: The rate of overall intrahospital death was 46%. Death until last follow‐up occurred in 8/17 (47%) in the REP and in 7/11 (63%) of the NOREP group. Favorable outcomes were observed in 35.7% of the patients: 8/17 (47%) in REP and in 2/11 (18.1%) in NOREP. NIH stroke scale scores were significantly lower in patients with favorable outcomes. Intracranial hemorrhage was observed in 6/28 (21.4%) of the patients (all in REP group). Twenty patients were treated with anticoagulants within the first 24 h. No hemorrhage was observed in those treated with enoxaparin, while three occurred in subjects treated with unfractionated heparin. Conclusion: Together with other series, our results underscore the relevance of NIH stroke scale at admission as a prognostic marker, the importance of reperfusion to improve outcomes, and the need of clinical trials to compare the impact of treatment with anticoagulants within first 24 h in basilar artery occlusion. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
35. Management of central nervous system demyelinating diseases during the coronavirus disease 2019 pandemic: a practical approach
- Author
-
APÓSTOLOS-PEREIRA, Samira Luisa, SILVA, Guilherme Diogo, DISSEROL, Caio César Diniz, FEO, Lucas Bueno, MATOS, Aline de Moura Brasil, SCHOEPS, Vinicius Andreoli, GOMES, Ana Beatriz Ayroza Galvão Ribeiro, BOAVENTURA, Mateus, MENDES, Maria Fernanda, and CALLEGARO, Dagoberto
- Subjects
Coronavirus ,Coronavírus ,Multiple Sclerosis ,Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos ,Neuromielite Óptica ,Neuromyelitis Optica Spectrum Disorders ,Esclerose Múltipla ,Imunossupressor ,Drug Side Effects ,Immunosuppressive Agents - Abstract
Background: The novel coronavirus disease 2019 (COVID-19) pandemic poses a potential threat to patients with autoimmune disorders, including multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD). Such patients are usually treated with immunomodulatory or immunosuppressive agents, which may tamper with the organism’s normal response to infections. Currently, no consensus has been reached on how to manage MS and NMOSD patients during the pandemic. Objective: To discuss strategies to manage those patients. Methods: We focus on how to 1) reduce COVID-19 infection risk, such as social distancing, telemedicine, and wider interval between laboratory testing/imaging; 2) manage relapses, such as avoiding treatment of mild relapse and using oral steroids; 3) manage disease-modifying therapies, such as preference for drugs associated with lower infection risk (interferons, glatiramer, teriflunomide, and natalizumab) and extended-interval dosing of natalizumab, when safe; 4) individualize the chosen MS induction-therapy (anti-CD20 monoclonal antibodies, alemtuzumab, and cladribine); 5) manage NMOSD preventive therapies, including initial therapy selection and current treatment maintenance; 6) manage MS/NMOSD patients infected with COVID-19. Conclusions: In the future, real-world case series of MS/NMOSD patients infected with COVID-19 will help us define the best management strategies. For the time being, we rely on expert experience and guidance. RESUMO Introdução: A mais recente pandemia causada pelo coronavírus SARS-CoV-2 (COVID-19, do inglês coronavirus disease 2019) representa uma ameaça potencial para pacientes com doenças autoimunes, incluindo esclerose múltipla (EM) e transtorno do espectro de neuromielite óptica (NMOSD, do inglês neuromyelitis optica spectrum disorders). Esses pacientes são geralmente tratados com medicamentos imunomoduladores ou imunossupressores que podem alterar a resposta normal do organismo a infecções. Até o momento, não há consenso sobre como o manejo dos pacientes com EM e NMOSD deve ser realizado durante a pandemia. Objetivo: Discutir estratégias para manejar esses pacientes. Métodos: Focamos em como 1) reduzir o risco de infecção por COVID-19, como distanciamento social, telemedicina e exames laboratoriais e de imagem em intervalos mais amplos; 2) manejo de surtos, incluindo evitar tratamento de surto leve e uso de corticoide oral; 3) gerenciar terapias modificadoras de doença, como a preferência por medicamentos associados a menor risco de infecção (interferons, glatirâmer, teriflunomida e natalizumabe) e infusão em intervalo estendido de natalizumabe, quando seguro; 4) individualizar a escolha da terapia de indução para EM (anticorpos monoclonais anti-CD20, alentuzumabe e cladribina); 5) manejar terapias preventivas de NMOSD, incluindo seleção inicial de terapia e manutenção do tratamento atual; 6) manejar pacientes com EM/NMOSD que foram infectados por COVID-19. Conclusão: No futuro, séries de casos de pacientes com MS/NMOSD infectados com COVID-19 nos ajudará a definir as melhores estratégias de manejo. Por enquanto, contamos com a experiência e orientação especializadas.
- Published
- 2020
36. Case Report: Neurodegenerative Diseases After Severe Acute Respiratory Syndrome Coronavirus 2 Infection, a Report of Three Cases: Creutzfeldt–Jakob Disease, Rapidly Progressive Alzheimer's Disease, and Frontotemporal Dementia.
- Author
-
Pimentel, Gabriela Almeida, Guimarães, Thiago Gonçalves, Silva, Guilherme Diogo, and Scaff, Milberto
- Subjects
CREUTZFELDT-Jakob disease ,CORONAVIRUS diseases ,COVID-19 ,ALZHEIMER'S disease ,REPORTING of diseases ,FRONTOTEMPORAL dementia - Abstract
The relationship between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and neurodegenerative diseases is yet to be fully clarified. Rapid worsening and even new-onset cases of those disorders have been reported in association with coronavirus disease 2019 (COVID-19). We describe three cases of neurodegenerative diseases in patients with SARS-CoV-2: a case of Creutzfeldt–Jakob disease during the COVID-19 acute phase, to our knowledge, is the second one described in the literature; a rapidly progressive Alzheimer's Disease; and a patient with frontotemporal dementia, and a quick decline of both cognitive and behavioral domains. This report suggests an association between SARS-CoV-2 infection and a higher probability of developing or accelerating neurodegenerative chronic neurologic conditions. We reinforce the need for a close cognitive follow-up in the aftermath of Sars-Cov2 infection. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
37. Cognitive outcomes of anti‐amyloid‐β monoclonal antibodies in patients with Alzheimer's disease: A systematic review and meta‐analysis of randomized controlled trials.
- Author
-
Fernandez, Paulo Eduardo Lahoz and Silva, Guilherme Diogo
- Abstract
Background: For the last 20 years, the amyloid‐beta (Aβ) cascade hypothesis has been dominant in the research of disease‐modifying therapeutics, with spent of financial and clinical resources in potential drugs targeting Aβ peptide production or clearance. (1) In this context, monoclonal antibodies targeting beta‐amyloid (Aβ‐mAbs) are being tested to reduce the amyloid burden in patients with Alzheimer's Disease (AD). (2) However, the cognitive impact of Aβ‐mAbs remains controversial. (3) We aim to evaluate the conflicting results of previous studies using a meta‐analysis. Method: We searched PubMed, Embase, and Cochrane databases, following until April 2021, using the search terms: ''Alzheimer's disease'' OR ''dementia'' cross‐referenced with ''monoclonal antibodies'', considering the synonyms. Eligible articles were randomized clinical trials with Aβ‐mAbs that reported cognitive outcomes. The cognitive function was assessed by Alzheimer's Disease Assessment Scale (ADAS‐cog) and Mini‐Mental State‐Exam (MMSE). We performed a meta‐analysis comparing mAbs and placebo, considering a minimal significant clinical change of 3 points in ADAS‐Cog and 2 points in MMSE. Result: We found 12 eligible studies in 443 identified records, involving 6736 patients, mean age 71.4 ± 2. We found a small benefit in cognitive outcomes in patients treated with Aβ‐mAbs: ADAS‐Cog: mean difference (MD) = ‐ 0.65; 95% CI (‐1.05 to ‐ 0.26); I² = 12%; (p = 0.001) and MMSE: MD = 0.40; 95% CI (0.18 to 0.63); I² = 10%; (p = 0.0004). The Funnel plot and Egger's test did not show publication bias. MD was below the minimal clinically relevant change in both scales. Conclusion: Aβ‐mAbs may have a positive cognitive benefit in AD patients. However, the impact magnitude is small, not reaching minimal clinically relevant change for these scales. References: (1) Panza F, Lozupone M, Seripa D, Imbimbo BP. Amyloid‐β immunotherapy for alzheimer disease: Is it now a long shot? Ann Neurol. 2019 Mar;85(3):303–15. (2) Liu J, Yang B, Ke J, Li W, Suen W‐C. Antibody‐Based Drugs and Approaches Against Amyloid‐β Species for Alzheimer's Disease Immunotherapy. Drugs Aging. 2016 Oct;33(10):685–97. (3) Panza F, Lozupone M, Logroscino G, Imbimbo BP. A critical appraisal of amyloid‐β‐targeting therapies for Alzheimer disease. Nat Rev Neurol. 2019 Feb;15(2):73–88. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
38. Considering the neurological health needs of LGBTQIA people
- Author
-
Silva, Guilherme Diogo
- Published
- 2022
- Full Text
- View/download PDF
39. Understanding MOG antibody-associated disease in Brazil.
- Author
-
Callegaro, Dagoberto and Silva, Guilherme Diogo
- Published
- 2023
- Full Text
- View/download PDF
40. Acute chorea: case series from the emergency room of a Brazilian tertiary-level center.
- Author
-
SILVA, Guilherme Diogo, PARMERA, Jacy Bezerra, and HADDAD, Monica Santoro
- Abstract
Copyright of Arquivos de Neuro-Psiquiatria is the property of Thieme Medical Publishing Inc. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2021
- Full Text
- View/download PDF
41. Cannabidiol in the Treatment of Epilepsy: A Focused Review of Evidence and Gaps.
- Author
-
Silva, Guilherme Diogo, Del Guerra, Felipe Borelli, de Oliveira Lelis, Maira, and Pinto, Lécio Figueira
- Subjects
CANNABIDIOL ,LENNOX-Gastaut syndrome ,PEOPLE with epilepsy ,PARTIAL epilepsy ,KNOWLEDGE gap theory ,EPILEPSY - Abstract
Approximately one third of epilepsy patients do not become seizure free with antiseizure medications. This treatment gap motivates research for new therapeutic options, such as cannabidiol (CBD). CBD differs from other cannabis derivatives because of its consistent efficacy and lack of a psychoactive effect. CBD can be recommended as adjunctive therapy in patients with Dravet and Lennox-Gastaut syndromes. The most common adverse effects (AEs) are drowsiness, reduced appetite, diarrhea, and vomiting. Transaminase elevation is the most common AE that leads to CBD discontinuation. Coadministration with valproate may increase the risk of hepatotoxicity. The combination of CBD and clobazam may increase both the effectiveness and the risk of AEs associated with these drugs. The most striking gaps in knowledge are the efficacy and optimal dose of CBD for adults with focal epilepsies, the long-term safety of CBD use, and strategies to improve access to CBD for people living with epilepsy. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
42. Spinal Cord Injury, Vertebral Artery Dissection, and Cerebellar Strokes After Chiropractic Manipulation.
- Author
-
Ramos, Gabriel Bortoli, Ranzani Martins, Rebecca, Carvalhinho Carlos de Souza, Julia, Falcão, Fernando Cavalcanti de Sá e Benevides, Lopes, Cesar Castello Branco, Gargioni de Andrade, Andre Luiz, and Silva, Guilherme Diogo
- Published
- 2022
- Full Text
- View/download PDF
43. A Woman With Eosinophilic Brainstem Meningoencephalitis.
- Author
-
Ferreira, Lucas Fernandes, Di Pace, Filipe Tupinamba, and Silva, Guilherme Diogo
- Published
- 2022
- Full Text
- View/download PDF
44. Teaching Video NeuroImage: Dissociation of Abdominal Reflexes in Rheumatoid Atlantoaxial Subluxation.
- Author
-
Brum, Igor Vilela and Silva, Guilherme Diogo
- Published
- 2022
- Full Text
- View/download PDF
45. Comparison of the clinical syndromes of anti-GABAa versus anti-GABAb associated autoimmune encephalitis: A systematic review.
- Author
-
Ronchi, Nathalia Rossoni and Silva, Guilherme Diogo
- Subjects
- *
ENCEPHALITIS , *ANTI-NMDA receptor encephalitis , *SMALL cell lung cancer - Abstract
The main objective of this article is to improve our understanding of the differences and similarities of these two anti-gamma-aminobutyric acid receptor encephalitis, anti-GABAaR and anti-GABAbR. The data were systematically collected and we found 26 studies: seven studies and 37 patients corresponded to anti-GABAaR encephalitis, and 21 manuscripts and 116 patients were diagnosed with anti-GABAbR encephalitis. Both anti-GABAR encephalitis were marked by prominent seizures. Anti-GABAaR patients were younger and showed multifocal encephalitis. On the other hand, anti-GABAbR patients were older and showed temporal limbic encephalitis. Tumor occurred in a fifth of anti-GABAaR encephalitis and in half of anti-GABAbR encephalitis. The main tumor associated with anti-GABAbR encephalitis is SCLC, whereas the most common tumor associated with anti-GABAaR encephalitis was thymoma. Our data confirms the differences in clinical features between both encephalitis. • Even antibodies against different classes of the same receptor cause distinctive clinical phenotypes • Anti-GABAaR patients were younger and showed multifocal encephalitis. • Anti-GABAbR patients were older and showed temporal limbic encephalitis • The main tumor associated with anti-GABAbR encephalitis is small cell lung cancer. • However, whereas the most common tumor associated with anti-GABAaR encephalitis was thymoma. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
46. Primary angiitis of the central nervous system as a mimic of multiple sclerosis: A case report.
- Author
-
de Souza Tieppo, Eduardo Macedo, da Silva, Tomás Fraga Ferreira, de Araujo, Roger Santana, Silva, Guilherme Diogo, Paes, Vitor Ribeiro, de Medeiros Rimkus, Carolina, Tinone, Gisela, Pereira, Samira Apóstolos, and Callegaro, Dagoberto
- Subjects
- *
CENTRAL nervous system , *MULTIPLE sclerosis , *VASCULITIS , *MAGNETIC resonance imaging , *DIFFERENTIAL diagnosis - Abstract
Primary angiitis of the central nervous system is a rare inflammatory vasculopathy and it is a difficult diagnosis to make because of its kaleidoscopic presentation and its multiple mimics, including multiple sclerosis. A 21-year-old men presented a four-year history of progressive gait deterioration. Magnetic resonance imaging of the brain and spine showed hyperintense round-shaped lesions on T2 images, many with contrast enhancement, in supra/infratentorial and spinal segments. He received treatment for multiple sclerosis but presented clinical worsening, and follow-up neuroimaging showed persistent contrast enhancement lesions and a cerebellar hematoma. Brain biopsy was performed and demonstrated inflammatory infiltrations in blood vessels. The patient received 6 monthly schedules of 5 g methylprednisolone and 1 g cyclophosphamide with clinical stabilization. Our patient presented a primary angiitis central nervous system according to the Birnbaum and Hellmann proposed criteria. This case reinforces the importance of advancing the differential diagnosis of patients that present red flags in brain neuroimaging. The presence of the micro/macrobleeds and persistent contrast enhancing lesions should raise the suspicion of vasculitis in the differential diagnosis of multiple sclerosis. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
47. Young-Onset Alzheimer Dementia Due to a Novel Pathogenic Presenilin 1 Variant Initially Misdiagnosed as Autoimmune Encephalitis.
- Author
-
Ronchi NR, Castro MA, Coutinho AM, Lucato LT, Silva GD, Brucki SM, Kok F, Trés ES, Nóbrega PR, Freua F, Nitrini R, and Simabukuro MM
- Subjects
- Humans, Female, Hashimoto Disease diagnosis, Hashimoto Disease cerebrospinal fluid, Adult, Age of Onset, Alzheimer Disease diagnosis, Alzheimer Disease cerebrospinal fluid, Presenilin-1 genetics, Encephalitis diagnosis, Encephalitis cerebrospinal fluid, Diagnostic Errors
- Abstract
Objectives: Pathogenic variants in presenilin 1 (PSEN1) are related to early-onset Alzheimer disease (AD) and may occur as de novo variants. In comparison with sporadic forms, it can present with psychiatric manifestations, seizures, myoclonus, and focal presentation. Because PSEN1 can occur in young patients who lack a family history of neurologic disorders and because these symptoms are also frequent in autoimmune encephalitis (AE), diagnosis may be overlooked. Our aim was to demonstrate the challenge in diagnosing young patients with neurodegenerative diseases that simulate AE., Methods: We describe a case of a young patient with insidious progressive dementia, myoclonus, seizures, and aphasia, with no family history of dementia, along with signs suggestive of neuroinflammation on brain MRI and CSF examination., Results: She was initially misdiagnosed as having AE. Further investigation was performed, leading to the discovery of a novel and de novo pathogenic variant in PSEN1., Discussion: This case demonstrates the importance of considering PSEN1 in young patients with insidious progressive dementia with atypical clinical and neuroimaging features, even in patients without a family history of neurologic disorders. Not adhering to published criteria of possible and probable AE and overinterpretation of subtle inflammatory findings in CSF and MRI contribute to misdiagnosis.
- Published
- 2024
- Full Text
- View/download PDF
48. Histoplasmosis in a fingolimod-treated patient: case report and scoping review.
- Author
-
Oliveira VF, Silva GDD, Silva LT, Gonçalves VL, Rivas PE, Marques AC, Taborda M, Magri ASGK, Apóstolos-Pereira SL, Callegaro D, and Magri MMC
- Subjects
- Humans, Female, Adult, Antifungal Agents adverse effects, Antifungal Agents therapeutic use, Immunosuppressive Agents adverse effects, Histoplasma, Histoplasmosis drug therapy, Histoplasmosis diagnosis, Fingolimod Hydrochloride adverse effects, Multiple Sclerosis, Relapsing-Remitting drug therapy
- Abstract
Fingolimod is a sphingosine-1-phosphate receptor modulator used to treat multiple sclerosis. While fingolimod has been associated with an increased risk of cryptococcal meningitis, its correlation with other deep mycoses remains unclear. In this study, we conducted a scoping review of fingolimod associated with histoplasmosis, based on a case report, a literature review, and data from the FDA Adverse Events Reporting System (FAERS) as of January 24th, 2023. A 30-year-old Brazilian woman diagnosed with relapsing-remitting multiple sclerosis, receiving a daily dose of 0.5 mg of fingolimod, presented with a two-month history of fever and unintended weight loss, accompanied by lymphadenopathy, splenomegaly, and lung involvement was investigated. Biopsy of a lung nodule revealed fungal structures suggestive of Histoplasma sp. Additionally, serological testing yielded positive for Histoplasma capsulatum. Disseminated histoplasmosis should be considered in the differential diagnosis of febrile syndromes in patients undergoing fingolimod therapy for multiple sclerosis, particularly in the Americas, where this mycosis is endemic. Treatment with itraconazole and modification of immunotherapy can achieve excellent clinical outcomes.
- Published
- 2024
- Full Text
- View/download PDF
49. Brazilian consensus recommendations on the diagnosis and treatment of autoimmune encephalitis in the adult and pediatric populations.
- Author
-
Dutra LA, Silva PVC, Ferreira JHF, Marques AC, Toso FF, Vasconcelos CCF, Brum DG, Pereira SLDA, Adoni T, Rocha LJA, Sampaio LPB, Sousa NAC, Paolilo RB, Pizzol AD, Costa BKD, Disserol CCD, Pupe C, Valle DAD, Diniz DS, Abrantes FF, Schmidt FDR, Cendes F, Oliveira FTM, Martins GJ, Silva GD, Lin K, Pinto LF, Santos MLSF, Gonçalves MVM, Krueger MB, Haziot MEJ, Barsottini OGP, Nascimento OJMD, Nóbrega PR, Proveti PM, Castilhos RMD, Daccach V, and Glehn FV
- Subjects
- Humans, Brazil, Child, Adult, Hashimoto Disease diagnosis, Hashimoto Disease therapy, Delphi Technique, Autoantibodies blood, Encephalitis diagnosis, Encephalitis therapy, Encephalitis immunology, Consensus
- Abstract
Background: Autoimmune encephalitis (AIE) is a group of inflammatory diseases characterized by the presence of antibodies against neuronal and glial antigens, leading to subacute psychiatric symptoms, memory complaints, and movement disorders. The patients are predominantly young, and delays in treatment are associated with worse prognosis., Objective: With the support of the Brazilian Academy of Neurology (Academia Brasileira de Neurologia, ABN) and the Brazilian Society of Child Neurology (Sociedade Brasileira de Neurologia Infantil, SBNI), a consensus on the diagnosis and treatment of AIE in Brazil was developed using the Delphi method., Methods: A total of 25 panelists, including adult and child neurologists, participated in the study., Results: The panelists agreed that patients fulfilling criteria for possible AIE should be screened for antineuronal antibodies in the serum and cerebrospinal fluid (CSF) using the tissue-based assay (TBA) and cell-based assay (CBA) techniques. Children should also be screened for anti-myelin oligodendrocyte glucoprotein antibodies (anti-MOG). Treatment should be started within the first 4 weeks of symptoms. The first-line option is methylprednisolone plus intravenous immunoglobulin (IVIG) or plasmapheresis, the second-line includes rituximab and/or cyclophosphamide, while third-line treatment options are bortezomib and tocilizumab. Most seizures in AIE are symptomatic, and antiseizure medications may be weaned after the acute stage. In anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis, the panelists have agreed that oral immunosuppressant agents should not be used. Patients should be evaluated at the acute and postacute stages using functional and cognitive scales, such as the Mini-Mental State Examination (MMSE), the Montreal Cognitive Assessment (MoCA), the Modified Rankin Scale (mRS), and the Clinical Assessment Scale in Autoimmune Encephalitis (CASE)., Conclusion: The present study provides tangible evidence for the effective management of AIE patients within the Brazilian healthcare system., Competing Interests: LAD reports that she has received a grant for the Brazilian Autoimmune Encephalitis Network (Rede Brasileira de Encefalites Autoimunes), from Laboratório Fleury., (The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/).)
- Published
- 2024
- Full Text
- View/download PDF
50. The myths that drive therapeutic inertia in multiple sclerosis: a cost-effectiveness analysis of high-efficacy drugs in Brazil.
- Author
-
Pipek LZ, Mahler JV, Nascimento RFV, Becker J, Apóstolos-Pereira SL, Adoni T, Silva GD, and Callegaro D
- Subjects
- Humans, Cost-Effectiveness Analysis, Brazil, Glatiramer Acetate therapeutic use, Multiple Sclerosis drug therapy, Multiple Sclerosis, Relapsing-Remitting drug therapy
- Abstract
Competing Interests: The authors had regular visits and event funding from Biogen, Merck, Novartis, Roche, EMS, Alexion, and Horizon.
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.